Biological therapies for eosinophilic gastrointestinal diseases - 04/07/18
, Ikuo Hirano, MD bAbstract |
The scientific basis and the clinical application of mAb therapies that target specific immunologic pathways for eosinophilic gastrointestinal diseases are areas of active interest. There is a growing recognition of a subset of patients with eosinophilic esophagitis whose disease does not respond well to topical steroids or elimination diets. In addition, long-term use of corticosteroids presents possible risks that are currently being evaluated. Systemic therapy with a biologic agent offers potential advantages as a global approach that could limit the need for multiple, locally active medical therapies and allergen avoidance. The identification of novel biologic strategies is ongoing, and the recent validation of instruments and outcome measures to assess disease activity has proved essential in demonstrating efficacy. Studies using biologics that target IL-13 pathways in the treatment of eosinophilic esophagitis have demonstrated substantial promise.
Le texte complet de cet article est disponible en PDF.Key words : Eosinophilic esophagitis, gastroesophageal reflux disease, dysphagia, food allergy, esophageal strictures, esophagitis
Abbreviations used : CRTH2, EGID, EoE, eos, EREFS, PRO, RDBPCT, Siglec-8, STAT6, TSLP
Plan
| The authors acknowledge grant support from the National Institutes of Health Consortium of Eosinophilic Gastrointestinal disease Researchers (CEGIR; grant no. U54 AI117804), which is part of the Rare Disease Clinical Research Network, an initiative of the Office of Rare Diseases Research, the National Center for Advancing Translational Sciences (NCATS), and is funded through a collaboration between the National Institute of Allergy and Infectious Diseases, the National Institute of Diabetes and Digestive and Kidney Diseases, and the NCATS. CEGIR is also supported by patient advocacy groups including APFED CURED and EFC. J.B.W. receives grant support from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; grant no. K08DK097721). |
|
| Disclosure of potential conflict of interest: I. Hirano reports consulting fees and research funding from Regeneron, Receptos, Shire, Adare, and Allakos outside the submitted work. J. B. Wechsler declares no relevant conflicts of interest. |
Vol 142 - N° 1
P. 24 - juillet 2018 Retour au numéro
Article précédent
- Epithelial origin of eosinophilic esophagitis
- Mark Rochman, Nurit P. Azouz, Marc E. Rothenberg
- Environmental factors and eosinophilic esophagitis
- Elizabeth T. Jensen, Evan S. Dellon
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?